327046-79-7

Basic information

• Product Name: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester;N-(4-BroMo-2-nitrophenyl)carbaMic Acid tert-Butyl Ester;tert-butyl (4-bromo-2-nitrophenyl)carbamate;(4-Bromo-2-nitro-phenyl)-carbamic acid tert-butyl ester
• CAS NO: 327046-79-7
• Molecular Formula: C₁₁H₁₃BrN₂O₄
• Molecular Weight: 317.13592
• Product Categories: Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 327046-79-7.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 337.8±32.0 °C(Predicted)
• Appearance: /
• Density: 1.535±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform, Dichloromethane, Methanol
• PKA: 11.70±0.70(Predicted)
• CAS DataBase Reference: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(327046-79-7)
• EPA Substance Registry System: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(327046-79-7)

Safety Data

• Hazardous Substances Data: 327046-79-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

tert-butyl N-(4-bromo-2-nitrophenyl)carbamate is a reactant used in the optimization of selective HDAC1/HDAC2 inhibitor and preparation of selective HDAC inhibitors.

Upstream product

• 1228392-59-3 N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 875-51-4 4-Bromo-2-nitroaniline 
• 131818-17-2 tert-butyl (4-bromophenyl)carbamate 
• 88-74-4 2-nitro-aniline 

Downstream Products

• 1306598-86-6 6-(4-fluorophenyl)-3-(imidazo[1,2-a]pyridin-3-yl)-2-methylquinoxaline 
• 1306598-88-8 7-(4-fluorophenyl)-2-(2-methylimidazo[1,2-b]pyridazin-3-yl)quinoxaline 
• 335255-43-1 tert-butyl 2-amino-4-(thiophen-2-yl)phenylcarbamate 
• 937728-82-0 tert-butyl N-(2-(6-chloronicotinamido)-4-(thiophen-2-yl)phenyl)carbamate 
• 1538608-34-2 N-(2-amino-5-(4-methylthiophen-2-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 335255-30-6 (2-amino-4-thiophen-3-yl-phenyl)-carbamic acid tert.-butyl ester 
• 1300078-64-1 C₁₆H₂₀N₂O₂S 
• 335255-33-9 tert-butyl (3-amino-4-biphenylyl)carbamate 
• 1538608-35-3 N-(4-amino-4'-fluoro-[1,1'-biphenyl]-3-yl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 937728-83-1 tert-Butyl [2-{[(6-Chloropyridin-3-yl)carbonyl]amino}-4-(3-thienyl)phenyl]-carbamate 
• 937728-81-9 t-butyl {3-[(6-chloropyridine-3-carbonyl)amino][1,1'-biphenyl]-4-yl}carbamate 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

HDAC DEGRADER

The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may

URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES

The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autos